The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing-Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis

F. Barkhof, R. Jong, N. Sfikas, A. de Vera, G. Francis, J. Cohen

Research output: Contribution to journalArticleAcademicpeer-review

Original languageUndefined/Unknown
Pages (from-to)1704-1713
JournalMultiple Sclerosis
Issue number13
Publication statusPublished - 2014

Cite this